These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 29571622)

  • 1. Comparison between activated clotting time and anti-activated factor X activity for the monitoring of unfractionated heparin therapy in patients with aortic aneurysm undergoing an endovascular procedure.
    Dieplinger B; Egger M; Luft C; Hinterreiter F; Pernerstorfer T; Haltmayer M; Mueller T
    J Vasc Surg; 2018 Aug; 68(2):400-407. PubMed ID: 29571622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partial thromboplastin time is more predictive of bleeding than anti-Xa levels in heparinized pediatric patients after cardiac surgery.
    Oladunjoye OO; Sleeper LA; Nair AG; Trenor CC; VanderPluym C; Kheir JN; Emani SM
    J Thorac Cardiovasc Surg; 2018 Jul; 156(1):332-340.e1. PubMed ID: 29709361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unfractionated heparin dosing in young infants: clinical outcomes in a cohort monitored with anti-factor Xa levels.
    Schechter T; Finkelstein Y; Ali M; Kahr WH; Williams S; Chan AK; Deveber G; Brandão LR
    J Thromb Haemost; 2012 Mar; 10(3):368-74. PubMed ID: 22244010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulant Effect of Standard Dose Heparin During Peripheral Endovascular Intervention.
    Nissborg E; Wahlgren CM
    Ann Vasc Surg; 2019 Oct; 60():286-292. PubMed ID: 31075466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PiCT
    Brisset AC; Ferrández A; Krause M; Rathbun S; Marlar R; Korte W
    J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors: Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial.
    Dillinger JG; Ducrocq G; Elbez Y; Cohen M; Bode C; Pollack C; Nicolau JC; Henry P; Kedev S; Wiviott SD; Sabatine MS; Mehta SR; Steg PG
    Circ Cardiovasc Interv; 2018 Jun; 11(6):e006084. PubMed ID: 29895599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining optimal activated clotting time for percutaneous coronary intervention: A systematic review and Bayesian meta-regression.
    Mottillo S; Filion KB; Joseph L; Eisenberg MJ
    Catheter Cardiovasc Interv; 2017 Feb; 89(3):351-366. PubMed ID: 27545117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifactor Xa Activity for the Management of Anticoagulation during Cardiac Surgery.
    Reyher C; Würfel C; Lindhoff-Last E; Meybohm P; Zacharowski K; Moritz A; Schindewolf M; Weber CF
    Thorac Cardiovasc Surg; 2016 Sep; 64(6):494-500. PubMed ID: 26757210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can an anti-Xa assay for unfractionated heparin be used to assess the presence of rivaroxaban in critical situations?
    Shin H; Koh EH; Lee GW; Song HN; Kim HY; Park S
    J Vasc Surg Venous Lymphat Disord; 2020 Sep; 8(5):741-747. PubMed ID: 32113855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated Clotting Time (ACT) for Monitoring of Low-Dose Heparin: Performance Characteristics in Healthy Adults and Critically Ill Patients.
    Wehner JE; Boehne M; David S; Brand K; Tiede A; Bikker R
    Clin Appl Thromb Hemost; 2020; 26():1076029620975494. PubMed ID: 33350327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of baseline activated clotting time-guided heparin administration in reducing bleeding events during transfemoral transcatheter aortic valve implantation.
    Bernelli C; Chieffo A; Montorfano M; Maisano F; Giustino G; Buchanan GL; Chan J; Costopoulos C; Latib A; Figini F; De Meo E; Giannini F; Covello RD; Gerli C; Franco A; Agricola E; Spagnolo P; Cioni M; Alfieri O; Camici PG; Colombo A
    JACC Cardiovasc Interv; 2014 Feb; 7(2):140-151. PubMed ID: 24556092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of a Calculation-Free Weight-Based Unfractionated Heparin Nomogram With Anti-Xa Level Monitoring Compared With Activated Partial Thromboplastin Time.
    Kindelin NM; Anthes AM; Providence SM; Zhao X; Aspinall SL
    Ann Pharmacother; 2021 May; 55(5):575-583. PubMed ID: 32964730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.
    Vandiver JW; Vondracek TG
    Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulation monitoring during vascular surgery: accuracy of the Hemochron low range activated clotting time (ACT-LR).
    Tremey B; Szekely B; Schlumberger S; François D; Liu N; Sievert K; Fischler M
    Br J Anaesth; 2006 Oct; 97(4):453-9. PubMed ID: 16873382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Periprocedural management of anticoagulation for atrial fibrillation catheter ablation in direct oral anticoagulant-treated patients.
    Martin AC; Lessire S; Leblanc I; Dincq AS; Philip I; Gouin-Thibault I; Godier A
    Clin Cardiol; 2018 May; 41(5):646-651. PubMed ID: 29532536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance Assessment of a Multifaceted Unfractionated Heparin Dosing Protocol in Adult Patients on Extracorporeal Membrane Oxygenator.
    Al-Jazairi A; Raslan S; Al-Mehizia R; Dalaty HA; De Vol EB; Saad E; Alanazi M; Owaidah T
    Ann Pharmacother; 2021 May; 55(5):592-604. PubMed ID: 32959678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of activated clotting times obtained using Hemochron and Medtronic analysers in patients receiving anti-thrombin therapy during cardiac catheterisation.
    Chia S; Van Cott EM; Raffel OC; Jang IK
    Thromb Haemost; 2009 Mar; 101(3):535-40. PubMed ID: 19277416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical bleeding after pre-operative unfractionated heparin and low molecular weight heparin for coronary bypass surgery.
    Renda G; Di Pillo R; D'Alleva A; Sciartilli A; Zimarino M; De Candia E; Landolfi R; Di Giammarco G; Calafiore A; De Caterina R
    Haematologica; 2007 Mar; 92(3):366-73. PubMed ID: 17339186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Heparinization before Deployment of Endograft for Blunt Traumatic Aortic Injury in Severely Injured Patients.
    Makaloski V; Widenka H; Schönhoff F; Spanos K; Wyss TR; Schmidli J
    Ann Vasc Surg; 2021 Aug; 75():341-348. PubMed ID: 33556520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.